Accelerating Use of Unapproved Retatrutide Is Associated with Weaker Weight Loss and Increased Cardiovascular Symptoms

Overview

Clinical-note surveillance found rapidly growing use of products purported to contain retatrutide outside clinical trials. Compounded users lost 7.2% at six to twelve months versus 15.5% in trial participants, while early cardiovascular findings remain preliminary. An unapproved product leaves no ordinary prescription or claims trail. The study shows how evidence-linked review of clinical notes can identify emerging exposure and outcomes before structured surveillance exists. An unapproved product leaves no ordinary prescription or claims trail. The study shows how evidence-linked review of clinical notes can identify emerging exposure and outcomes before structured surveillance exists.

Study design & methods

Across a federated U.S. EHR network of 29 million patients, an LLM adjudicated full clinical notes for 983 people with a retatrutide mention. Exposure was confirmed for 652 and supply route for 531. Trial participants anchored 1:3:10:10 nearest-neighbor matching to compounded-retatrutide, semaglutide, and tirzepatide users on seven baseline covariates, producing groups of 89, 243, 890, and 890 patients. Across a federated U.S. EHR network of 29 million patients, an LLM adjudicated full clinical notes for 983 people with a retatrutide mention. Exposure was confirmed for 652 and supply route for 531. Trial participants anchored 1:3:10:10 nearest-neighbor matching to compounded-retatrutide, semaglutide, and tirzepatide users on seven baseline covariates, producing groups of 89, 243, 890, and 890 patients.

Principal findings

Among users with a known route, 71.2% obtained purported retatrutide outside a trial; use grew 1.8-fold per quarter. At six to twelve months, observed mean weight loss was 15.5% in trial participants and 7.2% among compounded users, similar to 7.7% with tirzepatide. Heart rate rose by 4.3 and 2.5 bpm at three months in the two retatrutide cohorts. Pooled retatrutide users had higher documented cardiovascular and neuropsychiatric symptom incidence than approved comparators, while MACE estimates were imprecise and not statistically significant. Among users with a known route, 71.2% obtained purported retatrutide outside a trial; use grew 1.8-fold per quarter. At six to twelve months, observed mean weight loss was 15.5% in trial participants and 7.2% among compounded users, similar to 7.7% with tirzepatide. Heart rate rose by 4.3 and 2.5 bpm at three months in the two retatrutide cohorts. Pooled retatrutide users had higher documented cardiovascular and neuropsychiatric symptom incidence than approved comparators, while MACE estimates were imprecise and not statistically significant.